Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anixa Biosciences IncANIX · Entity 6698 | Director | September 23, 2026 | September 25, 2026 |
| PARKERVISION INCPRKR · Entity 7682 | Director | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anixa Biosciences Inc
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,046,003 |
Reported balance
After 2026-09-23 transaction · row 1
1 source rowRow 1 · 2026-09-23 · Purchase · Acquired 49,036 · Balance 1,046,003 |
PARKERVISION INC
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.24 · Expires 2031-01-22 | Direct | 370,000 |
Reported balance
After 2026-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 370,000 · Balance 370,000 F1: Option is awarded as compensation for 2026 Board service. Option vests in two, equal bi-annual increments on July 22, 2026 and January 22, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Option is awarded as compensation for 2026 Board service. Option vests in two, equal bi-annual increments on July 22, 2026 and January 22, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 15, 2023 Filed Feb 12, 2024 22:36 UTC | PARKERVISION INC PRKR · Entity 7682 | OtherCommon Stock | 54,947 | $0.09 | $5,000.18 |
DisclosureSEC source: 0001437749-24-003790 · rdgdoc.xml · nonDerivative · entry 4 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,953,931 F2 · kind: Reporting Person acquired shares of common stock as quarterly interest-in-kind payments on a convertible note dated January 8, 2020 with a principal balance of $50,000 and a convertible note dated May 10, 2022 with a principal balance of $200,000. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 10:35 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option · Derivative | 16,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-23-036871 · ownership.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right-To-Buy, pursuant to a stock option grant dated January 2, 2014. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 10:35 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 16,000 | $2.58 | $41,200.00 |
DisclosureSEC source: 0001493152-23-036871 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 823,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2023 Filed Feb 12, 2024 22:36 UTC | PARKERVISION INC PRKR · Entity 7682 | OtherCommon Stock | 15,000 | $0.10 | $1,500.00 |
DisclosureSEC source: 0001437749-24-003790 · rdgdoc.xml · nonDerivative · entry 3 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,898,984 F3 · kind: Reporting Person acquired shares of common stock as quarterly interest payments in-kind on a convertible note dated June 19, 2019 with a principal balance of $25,000 and a convertible note dated September 13, 2019 with a principal balance of $50,000. Read SEC document |
| September 10, 2023 Filed Feb 12, 2024 22:36 UTC | PARKERVISION INC PRKR · Entity 7682 | OtherCommon Stock | 21,053 | $0.10 | $2,000.04 |
DisclosureSEC source: 0001437749-24-003790 · rdgdoc.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,883,984 F1 · kind: Reporting Person acquired shares of common stock as quarterly interest payments in-kind on a convertible note dated September 2018 with a principal balance of $100,000. Read SEC document |
| July 27, 2023 Filed Jul 31, 2023 18:36 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-23-026127 · ownership.xml · derivative · entry 3 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2023-11-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right-To-Buy, pursuant to a stock option grant dated November 8, 2013. Read SEC document |
| July 27, 2023 Filed Jul 31, 2023 18:36 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Tax withholdingCommon Stock | 87,042 | $3.55 | $308,999.10 |
DisclosureSEC source: 0001493152-23-026127 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 807,028 F1 · kind: The reporting persons exercised the stock options at this time due to their expiration on November 8, 2023. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to cover the exercise price of the stock options. Read SEC document |
| July 27, 2023 Filed Jul 31, 2023 18:36 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 120,000 | $2.58 | $309,000.00 |
DisclosureSEC source: 0001493152-23-026127 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2023 Filed Feb 12, 2024 22:36 UTC | PARKERVISION INC PRKR · Entity 7682 | OtherCommon Stock | 54,230 | $0.09 | $4,989.16 |
DisclosureSEC source: 0001437749-24-003790 · rdgdoc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,862,931 F2 · kind: Reporting Person acquired shares of common stock as quarterly interest-in-kind payments on a convertible note dated January 8, 2020 with a principal balance of $50,000 and a convertible note dated May 10, 2022 with a principal balance of $200,000. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 20:52 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001493152-23-000421 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-01-03 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2023. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 10:34 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option · Derivative | 40,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-22-027222 · ownership.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right-To-Buy, pursuant to a stock option grant dated February 15, 2013. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 10:34 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 40,000 | $2.58 | $103,000.00 |
DisclosureSEC source: 0001493152-22-027222 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 774,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 17:08 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GiftCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-026101 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,070 F1 · kind: Comprised of two separate bona fide gift transactions exempt under Rule 16b-5. No shares were sold in this transaction. Mr. Titterton transferred the shares to his children for estate planning purposes. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 10:21 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option · Derivative | 16,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-22-017926 · ownership.xml · derivative · entry 4 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right-To-Buy, pursuant to a stock option grant dated March 28, 2013. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 10:21 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionEmployee Stock Option · Derivative | 30,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001493152-22-017926 · ownership.xml · derivative · entry 3 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right-To-Buy, pursuant to a stock option grant dated September 19, 2012. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 10:21 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 16,000 | $2.58 | $41,200.00 |
DisclosureSEC source: 0001493152-22-017926 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 10:21 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Exercise / conversionCommon Stock | 30,000 | $2.58 | $77,250.00 |
DisclosureSEC source: 0001493152-22-017926 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2022 Filed Apr 27, 2022 10:01 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $2.79 | $27,900.00 |
DisclosureSEC source: 0001493152-22-011291 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 988,070 Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:15 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001493152-22-006627 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-10 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning March 31, 2022. Read SEC document |
| January 12, 2022 Filed Jan 13, 2022 10:23 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.28 | $16,400.00 |
DisclosureSEC source: 0001493152-22-001112 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,070 Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 09:54 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,000 | $3.20 | $6,400.00 |
DisclosureSEC source: 0001493152-22-001018 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,070 Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 09:21 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 6,000 | $3.08 | $18,480.00 |
DisclosureSEC source: 0001493152-22-000899 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 971,070 Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 09:36 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 11,000 | $3.08 | $33,880.00 |
DisclosureSEC source: 0001493152-22-000767 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,070 Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 13:32 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 18,244 | $4.76 | $86,841.44 |
DisclosureSEC source: 0001493152-21-026841 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 954,070 Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 09:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 30,000 | $4.21 | $126,300.00 |
DisclosureSEC source: 0001493152-21-017937 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 935,826 Read SEC document |
| July 16, 2021 Filed Jul 19, 2021 12:39 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 10,000 | $4.07 | $40,700.00 |
DisclosureSEC source: 0001493152-21-017157 · ownership.xml · nonDerivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 905,826 Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 12:39 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 2,200 | $3.65 | $8,030.00 |
DisclosureSEC source: 0001493152-21-017157 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895,826 Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 11:19 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 23,300 | $3.72 | $86,676.00 |
DisclosureSEC source: 0001493152-21-016912 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893,626 Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013456 · ownership.xml · derivative · entry 2 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F3 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 17:00 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001493152-21-013456 · ownership.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-01 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning June 30, 2021. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 10:32 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.99 | $19,950.00 |
DisclosureSEC source: 0001493152-21-009211 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 870,326 Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 11:06 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 45,000 | $4.84 | $217,800.00 |
DisclosureSEC source: 0001493152-21-006895 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,326 Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 16:44 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GiftCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-002803 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,326 F1 · kind: Comprised of two separate bona fide gift transactions exempt under Rule 16b-5. Read SEC document |
| September 11, 2020 Filed Sep 14, 2020 09:29 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 40,000 | $2.08 | $83,200.00 |
DisclosureSEC source: 0001493152-20-017705 · ownership.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,326 Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 16:45 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001513162-20-000175 · primary_doc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-08-13 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning August 31, 2020. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 10:30 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 24,500 | $2.27 | $55,615.00 |
DisclosureSEC source: 0001513162-20-000127 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 980,326 Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 11:43 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 31,083 | $2.27 | $70,558.41 |
DisclosureSEC source: 0001513162-20-000124 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955,826 Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 15:46 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,799 | $2.12 | $12,293.88 |
DisclosureSEC source: 0001513162-20-000054 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 924,743 Read SEC document |
| January 15, 2020 Filed Jan 16, 2020 11:22 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 5,000 | $3.32 | $16,600.00 |
DisclosureSEC source: 0001513162-20-000019 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 918,944 Read SEC document |
| January 14, 2020 Filed Jan 15, 2020 10:57 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | PurchaseCommon Stock | 7,400 | $3.22 | $23,828.00 |
DisclosureSEC source: 0001513162-20-000018 · primary_doc.xml · nonDerivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 913,944 Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 20:17 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 45,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0001513162-19-000227 · primary_doc.xml · derivative · entry 1 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-10-23 F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan. F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning November 30, 2019. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.92 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 16 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2026-01-14 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F9 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in four (4) equal installments on each of March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 15 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2026-01-14 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F9 · derivative.exercise_date: The option was originally granted on February 18, 2016 and vested in four (4) equal installments on each of March 31, 2016, June 30, 2016, September 30, 2016 and December 31, 2016. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 14 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2025-01-02 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F8 · derivative.exercise_date: The option was originally granted on January 2, 2015 and vested in four (4) equal installments on each of March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 13 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2025-01-02 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F8 · derivative.exercise_date: The option was originally granted on January 2, 2015 and vested in four (4) equal installments on each of March 31, 2015, June 30, 2015, September 30, 2015 and December 31, 2015. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 12 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2023-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F7 · derivative.exercise_date: The option was originally granted on January 2, 2014 and vested in four (4) equal installments on each of March 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 16,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 11 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2023-12-31 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F7 · derivative.exercise_date: The option was originally granted on January 2, 2014 and vested in four (4) equal installments on each of March 31, 2014, June 30, 2014, September 30, 2014 and December 31, 2014. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 120,000 | Not disclosed Strike: $2.58 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 10 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F6 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | Disposition to issuerEmployee Stock Option · Derivative | 120,000 | Not disclosed Strike: $0.67 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 9 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2023-11-08 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F6 · derivative.exercise_date: The option was originally granted on November 8, 2013 and vested in 36 consecutive monthly installments beginning on December 31, 2013. Read SEC document |
| September 20, 2019 Filed Sep 20, 2019 18:48 UTC | Anixa Biosciences Inc ANIX · Entity 6698 | GrantEmployee Stock Option · Derivative | 6,000 | Not disclosed Strike: $0.82 | Not disclosed |
DisclosureSEC source: 0001513162-19-000214 · primary_doc.xml · derivative · entry 8 Titterton Lewis H jr · CIK 0001499254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-07-17 F1 · kind: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F1 · price: These transactions involved an amendment of outstanding stock options due to a settlement pursuant to which these options that had been repriced on September 6, 2017 to $0.67, would have their exercise price changed to the exercise price immediately prior to that repricing, resulting in the deemed cancellation of the "old" options and the grant of replacement options. All of the other terms of the options remain the same, including without limitation, the number of shares underlying the options, the vesting periods of the options, and the expiration dates of the options. F5 · derivative.exercise_date: The option was originally granted on July 17, 2017 and vests and become exercisable in two equal installments on each September 30, 2017 and December 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.